Stock-Based Compensation |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-Based Compensation [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| STOCK-BASED COMPENSATION | NOTE 10 — STOCK-BASED COMPENSATION
The Company maintains the 2024 Equity Incentive Plan (the “2024 Plan”), under which 209,668 shares of common stock were reserved for issuance, as adjusted for the reverse stock split. That reserve reflects the increase from 153,846 shares approved by the stockholders on December 1, 2025 in connection with the MindWave transaction. Options outstanding under the 2024 Plan were 72,233 as of September 30, 2026, following the forfeiture of 58,804 unvested options described below. The 100,000 shares of common stock granted to the Chief Executive Officer and Chief Medical Officer during the three months ended June 30, 2025 were issued as stock grants outside the 2024 Plan reserve. The Apimeds Pharmaceuticals US, Inc. 2025 Equity Incentive Plan was also approved on December 1, 2025; no awards had been granted under the 2025 Plan as of September 30, 2026.
Stock option activity for the nine months ended September 30, 2026 was as follows:
All share and per-share amounts above have been adjusted for the 1-for-10 reverse stock split. The aggregate intrinsic value of options outstanding was $0 as of September 30, 2026 because the exercise price exceeded the market price of the Company’s common stock. As of September 30, 2026, unrecognized compensation cost related to unvested option awards was $64,127, which the Company expects to recognize over a weighted-average period of 2.1 years. During the three months ended September 30, 2026, 58,804 unvested options held by employees and consultants of Lokahi were forfeited when their service to the Company ended upon the deconsolidation of Lokahi; previously recognized compensation cost of $8,675 on those options was reversed and is included in discontinued operations. Vested options held by former employees and consultants of Lokahi remain exercisable in accordance with their terms. No options were granted during the three months ended September 30, 2026.
Stock-based compensation expense was recorded as follows:
The amounts above exclude the $8,113,318 of advisory shares committed for issuance described in Note 9, which was recognized in general and administrative expense in the three months ended March 31, 2026. Stock-based compensation of $219,376 for the nine months ended September 30, 2026 and $1,934,727 for the nine months ended September 30, 2025 on options held by employees and consultants of Lokahi is included in discontinued operations (see Note 3). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||